JP2017501711A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501711A5 JP2017501711A5 JP2016541346A JP2016541346A JP2017501711A5 JP 2017501711 A5 JP2017501711 A5 JP 2017501711A5 JP 2016541346 A JP2016541346 A JP 2016541346A JP 2016541346 A JP2016541346 A JP 2016541346A JP 2017501711 A5 JP2017501711 A5 JP 2017501711A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 58
- 239000000427 antigen Substances 0.000 claims 39
- 102000036639 antigens Human genes 0.000 claims 39
- 108091007433 antigens Proteins 0.000 claims 39
- 238000000034 method Methods 0.000 claims 34
- 239000012634 fragment Substances 0.000 claims 31
- 239000003814 drug Substances 0.000 claims 10
- 208000006673 asthma Diseases 0.000 claims 5
- 102000003816 Interleukin-13 Human genes 0.000 claims 4
- 108090000176 Interleukin-13 Proteins 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 102000009109 Fc receptors Human genes 0.000 claims 2
- 108010087819 Fc receptors Proteins 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010052285 Membrane Proteins Proteins 0.000 claims 2
- 102000018697 Membrane Proteins Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000012350 deep sequencing Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020092097A JP7504664B2 (ja) | 2013-12-20 | 2020-05-27 | 二重特異性抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919552P | 2013-12-20 | 2013-12-20 | |
| US61/919,552 | 2013-12-20 | ||
| US201461946547P | 2014-02-28 | 2014-02-28 | |
| US61/946,547 | 2014-02-28 | ||
| PCT/US2014/071193 WO2015095539A1 (en) | 2013-12-20 | 2014-12-18 | Dual specific antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020092097A Division JP7504664B2 (ja) | 2013-12-20 | 2020-05-27 | 二重特異性抗体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2017501711A JP2017501711A (ja) | 2017-01-19 |
| JP2017501711A5 true JP2017501711A5 (index.php) | 2018-02-08 |
| JPWO2015095539A5 JPWO2015095539A5 (index.php) | 2022-03-09 |
| JP7325166B2 JP7325166B2 (ja) | 2023-08-14 |
Family
ID=52293284
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016541346A Active JP7325166B2 (ja) | 2013-12-20 | 2014-12-18 | 二重特異性抗体 |
| JP2020092097A Active JP7504664B2 (ja) | 2013-12-20 | 2020-05-27 | 二重特異性抗体 |
| JP2023134016A Withdrawn JP2023179409A (ja) | 2013-12-20 | 2023-08-21 | 二重特異性抗体 |
| JP2025133768A Pending JP2025179073A (ja) | 2013-12-20 | 2025-08-08 | 二重特異性抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020092097A Active JP7504664B2 (ja) | 2013-12-20 | 2020-05-27 | 二重特異性抗体 |
| JP2023134016A Withdrawn JP2023179409A (ja) | 2013-12-20 | 2023-08-21 | 二重特異性抗体 |
| JP2025133768A Pending JP2025179073A (ja) | 2013-12-20 | 2025-08-08 | 二重特異性抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US10683348B2 (index.php) |
| EP (1) | EP3083682B1 (index.php) |
| JP (4) | JP7325166B2 (index.php) |
| KR (3) | KR102597804B1 (index.php) |
| CN (2) | CN114702594B (index.php) |
| BR (1) | BR112016011027A2 (index.php) |
| CA (2) | CA2931113C (index.php) |
| MX (2) | MX380937B (index.php) |
| RU (1) | RU2732032C2 (index.php) |
| WO (1) | WO2015095539A1 (index.php) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037960B1 (ru) | 2016-04-27 | 2021-06-15 | Эббви Инк. | Способ лечения эозинофильного эзофагита с применением антитела против il-13 |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| IL268554B2 (en) | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| FI3582806T3 (fi) | 2017-02-20 | 2023-09-07 | Dragonfly Therapeutics Inc | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja |
| EP3592851B1 (en) * | 2017-03-07 | 2024-11-27 | F. Hoffmann-La Roche AG | Method for discovery of alternative antigen specific antibody variants |
| AU2018247767B2 (en) | 2017-04-03 | 2025-01-30 | F. Hoffmann-La Roche Ag | Antibodies binding to STEAP-1 |
| PE20210256A1 (es) | 2017-04-05 | 2021-02-10 | Hoffmann La Roche | Anticuerpos anti-lag3 |
| WO2019062831A1 (zh) | 2017-09-29 | 2019-04-04 | 江苏恒瑞医药股份有限公司 | Il-5抗体、其抗原结合片段及医药用途 |
| AR114001A1 (es) | 2017-12-21 | 2020-07-08 | Hoffmann La Roche | Anticuerpos que se unen a hla- a2 / wt1 |
| WO2019149715A1 (en) | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Stabilized immunoglobulin domains |
| US20200354457A1 (en) | 2018-01-31 | 2020-11-12 | Hoffmann-La Roche Inc. | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
| KR20200118824A (ko) | 2018-02-08 | 2020-10-16 | 드래곤플라이 쎄라퓨틱스, 인크. | 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법 |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| SG11202009542PA (en) | 2018-03-29 | 2020-10-29 | Genentech Inc | Modulating lactogenic activity in mammalian cells |
| AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| AR115052A1 (es) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| MA53284A (fr) | 2018-08-08 | 2022-01-26 | Dragonfly Therapeutics Inc | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MX2021007307A (es) | 2018-12-21 | 2021-07-07 | Hoffmann La Roche | Anticuerpos que se unen a cd3. |
| US20220073630A1 (en) | 2018-12-28 | 2022-03-10 | Hoffmann-La Roche, Inc. | A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response |
| EP3930687A4 (en) | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
| AU2020251627A1 (en) | 2019-03-29 | 2021-11-11 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition containing antibody against IL-5 and use thereof |
| EP3947469A4 (en) | 2019-04-02 | 2022-12-14 | National Research Council of Canada | ANTIBODY VARIANTS WITH PH DEPENDENT ANTIGEN BINDING FOR SELECTIVE TARGETING OF SOLID TUMORS |
| EP3962924A1 (en) | 2019-05-03 | 2022-03-09 | Genentech, Inc. | Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform |
| CN117821393A (zh) | 2019-06-26 | 2024-04-05 | 豪夫迈·罗氏有限公司 | 具有sirt-1基因敲除的哺乳动物细胞系 |
| AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| CR20220019A (es) | 2019-07-31 | 2022-02-11 | Hoffmann La Roche | Anticuerpos que se fijan a gprc5d |
| WO2021018925A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
| EP4031579A2 (en) | 2019-09-18 | 2022-07-27 | F. Hoffmann-La Roche AG | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
| IL292899A (en) | 2019-11-15 | 2022-07-01 | Hoffmann La Roche | Prevention of visible particle formation in aqueous protein solutions |
| WO2021122875A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a2/mage-a4 |
| US11739142B2 (en) | 2019-12-18 | 2023-08-29 | Hoffmann-La Roche Inc. | Bispecific anti-CCL2 antibodies |
| CN115515678A (zh) | 2019-12-23 | 2022-12-23 | 基因泰克公司 | 载脂蛋白l1特异性抗体及其使用方法 |
| TW202140511A (zh) | 2020-01-15 | 2021-11-01 | 瑞士商赫孚孟拉羅股份公司 | 減少來自重組蛋白生產過程中的雜質之方法 |
| EP4127153A2 (en) | 2020-03-26 | 2023-02-08 | Genentech, Inc. | Modified mammalian cells having reduced host cell proteins |
| AR122018A1 (es) | 2020-05-06 | 2022-08-03 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y clec12a |
| JP2023520249A (ja) | 2020-05-15 | 2023-05-16 | エフ． ホフマン－ラ ロシュ アーゲー | 非経口タンパク質溶液中の可視粒子形成の防止方法 |
| JP2023525898A (ja) | 2020-05-19 | 2023-06-19 | エフ． ホフマン－ラ ロシュ アーゲー | 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用 |
| JP2023527918A (ja) | 2020-06-08 | 2023-06-30 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｈｂｖ抗体及び使用方法 |
| KR20230025665A (ko) | 2020-06-19 | 2023-02-22 | 에프. 호프만-라 로슈 아게 | Cd3에 결합하는 항체 |
| WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
| EP4168447A1 (en) | 2020-06-19 | 2023-04-26 | F. Hoffmann-La Roche AG | Antibodies binding to cd3 and cd19 |
| KR20230025673A (ko) | 2020-06-19 | 2023-02-22 | 에프. 호프만-라 로슈 아게 | CD3 및 FolR1에 결합하는 항체 |
| JP2023533217A (ja) | 2020-06-24 | 2023-08-02 | ジェネンテック， インコーポレイテッド | アポトーシス耐性細胞株 |
| EP4178529A1 (en) | 2020-07-07 | 2023-05-17 | F. Hoffmann-La Roche AG | Alternative surfactants as stabilizers for therapeutic protein formulations |
| CN116406377A (zh) | 2020-07-17 | 2023-07-07 | 基因泰克公司 | 抗notch2抗体及其使用方法 |
| JP2023539201A (ja) | 2020-08-28 | 2023-09-13 | ジェネンテック， インコーポレイテッド | 宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト |
| IL301366A (en) | 2020-09-24 | 2023-05-01 | Hoffmann La Roche | Mammalian cell lines with gene knockout |
| TW202233671A (zh) | 2020-10-20 | 2022-09-01 | 美商建南德克公司 | Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法 |
| JP2023549809A (ja) | 2020-11-16 | 2023-11-29 | エフ． ホフマン－ラ ロシュ アーゲー | Ｆａｂ高マンノースグリコフォーム |
| CR20230263A (es) | 2020-12-17 | 2023-08-21 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de estos |
| WO2022136140A1 (en) | 2020-12-22 | 2022-06-30 | F. Hoffmann-La Roche Ag | Oligonucleotides targeting xbp1 |
| US20240101675A1 (en) * | 2021-01-21 | 2024-03-28 | Biolojic Design Ltd. | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof |
| EP4288458A1 (en) | 2021-02-03 | 2023-12-13 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| JP2024512377A (ja) | 2021-03-12 | 2024-03-19 | ジェネンテック， インコーポレイテッド | 抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法 |
| EP4320444A1 (en) | 2021-04-09 | 2024-02-14 | F. Hoffmann-La Roche AG | Process for selecting cell clones expressing a heterologous polypeptide |
| EP4326855A1 (en) | 2021-04-19 | 2024-02-28 | Genentech, Inc. | Modified mammalian cells |
| WO2022246259A1 (en) | 2021-05-21 | 2022-11-24 | Genentech, Inc. | Modified cells for the production of a recombinant product of interest |
| WO2022263501A1 (en) | 2021-06-18 | 2022-12-22 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
| WO2023287663A1 (en) | 2021-07-13 | 2023-01-19 | Genentech, Inc. | Multi-variate model for predicting cytokine release syndrome |
| WO2023001884A1 (en) | 2021-07-22 | 2023-01-26 | F. Hoffmann-La Roche Ag | Heterodimeric fc domain antibodies |
| JP2024528217A (ja) | 2021-08-03 | 2024-07-26 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗体および使用方法 |
| AR127887A1 (es) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y plap |
| JP2025500334A (ja) | 2021-12-21 | 2025-01-09 | エフ． ホフマン－ラ ロシュ アーゲー | 加水分解活性を決定するための方法 |
| WO2023141445A1 (en) | 2022-01-19 | 2023-07-27 | Genentech, Inc. | Anti-notch2 antibodies and conjugates and methods of use |
| PE20242075A1 (es) * | 2022-03-03 | 2024-10-18 | Pfizer | Anticuerpos multiespecificos y usos de estos |
| CN119421890A (zh) | 2022-04-19 | 2025-02-11 | 豪夫迈·罗氏有限公司 | 改进的生产细胞 |
| EP4530299A4 (en) * | 2022-05-23 | 2025-11-19 | Regenecore Biotech Co Ltd | PREPARATION OF STABLE ANTIBODY |
| US20250223362A1 (en) | 2022-05-30 | 2025-07-10 | Hanall Biopharma Co., Ltd. | Anti-fcrn antibody or antigen binding fragment thereof with improved stability |
| JP2025517572A (ja) | 2022-06-03 | 2025-06-05 | エフ． ホフマン－ラ ロシュ アーゲー | 改良された産生細胞 |
| WO2023245187A2 (en) | 2022-06-17 | 2023-12-21 | Apogee Biologics, Inc. | Antibodies that bind interleukin 13 and methods of use |
| EP4558528A1 (en) | 2022-07-22 | 2025-05-28 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
| TW202423970A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法 |
| TW202430211A (zh) | 2022-10-10 | 2024-08-01 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法 |
| TW202423969A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法 |
| WO2024079069A1 (en) | 2022-10-12 | 2024-04-18 | F. Hoffmann-La Roche Ag | Method for classifying cells |
| CN120225684A (zh) | 2022-11-23 | 2025-06-27 | 豪夫迈·罗氏有限公司 | 用于增加重组蛋白表达的方法 |
| WO2024120516A1 (zh) | 2022-12-08 | 2024-06-13 | 南京诺唯赞生物科技股份有限公司 | 特异性结合rsv的抗体 |
| CN120693406A (zh) | 2022-12-12 | 2025-09-23 | 基因泰克公司 | 优化多肽唾液酸含量 |
| WO2024156672A1 (en) | 2023-01-25 | 2024-08-02 | F. Hoffmann-La Roche Ag | Antibodies binding to csf1r and cd3 |
| CN120826234A (zh) | 2023-03-06 | 2025-10-21 | 豪夫迈·罗氏有限公司 | 抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法 |
| WO2024191785A1 (en) | 2023-03-10 | 2024-09-19 | Genentech, Inc. | Fusions with proteases and uses thereof |
| TW202446789A (zh) | 2023-03-31 | 2024-12-01 | 美商建南德克公司 | 抗αｖβ８整合素抗體及使用方法 |
| AU2024269754A1 (en) | 2023-05-08 | 2025-10-23 | F. Hoffmann-La Roche Ag | Targeted interferon alpha fusion proteins and methods of use |
| WO2024263761A1 (en) | 2023-06-22 | 2024-12-26 | Genentech, Inc. | Antibodies and uses thereof |
| AU2024300993A1 (en) | 2023-07-26 | 2026-01-22 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
| WO2025032069A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025032071A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025040567A1 (en) | 2023-08-18 | 2025-02-27 | F. Hoffmann-La Roche Ag | Protease activatable fc domain binding molecules |
| JP2025036273A (ja) * | 2023-08-30 | 2025-03-14 | ファイザー・インク | 多重特異性抗体およびその使用 |
| AR133909A1 (es) | 2023-09-25 | 2025-11-12 | Hoffmann La Roche | ANTICUERPO QUE SE UNE A C3bBb |
| WO2025125386A1 (en) | 2023-12-14 | 2025-06-19 | F. Hoffmann-La Roche Ag | Antibodies that bind to folr1 and methods of use |
| WO2025137086A1 (en) | 2023-12-20 | 2025-06-26 | Genentech, Inc. | Reducing alpha-gal |
| WO2025132503A1 (en) | 2023-12-20 | 2025-06-26 | F. Hoffmann-La Roche Ag | Antibodies binding to ceacam5 |
| WO2025133042A2 (en) | 2023-12-22 | 2025-06-26 | F. Hoffmann-La Roche Ag | Activatable fusion proteins and methods of use |
| WO2025181189A1 (en) | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
| WO2025215060A1 (en) | 2024-04-11 | 2025-10-16 | F. Hoffmann-La Roche Ag | Antibodies that specifically bind modified oligonucleotides |
| WO2026006162A2 (en) | 2024-06-24 | 2026-01-02 | Genentech, Inc. | B vitamin modulation |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク． | 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
| CA2411374C (en) * | 2000-06-29 | 2012-10-30 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
| ATE477280T1 (de) * | 2001-06-28 | 2010-08-15 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| AU2003244817B2 (en) * | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| ZA200702427B (en) * | 2004-09-17 | 2008-12-31 | Domantis Ltd | Compositions monovalent for CD40L binding and methods of use |
| WO2008027236A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| CA2682406A1 (en) * | 2007-04-02 | 2008-10-09 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| AR075896A1 (es) * | 2009-03-20 | 2011-05-04 | Genentech Inc | Anticuerpos anti-her (factor de crecimiento epidermico) |
| WO2010136483A2 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| SG195196A1 (en) | 2011-05-27 | 2013-12-30 | Dutalys | Dual targeting |
| EP2981286A4 (en) * | 2013-04-05 | 2016-08-24 | Hoffmann La Roche | ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF |
-
2014
- 2014-12-18 CN CN202210315371.3A patent/CN114702594B/zh active Active
- 2014-12-18 MX MX2016006529A patent/MX380937B/es unknown
- 2014-12-18 BR BR112016011027A patent/BR112016011027A2/pt not_active Application Discontinuation
- 2014-12-18 WO PCT/US2014/071193 patent/WO2015095539A1/en not_active Ceased
- 2014-12-18 RU RU2016129247A patent/RU2732032C2/ru active
- 2014-12-18 CA CA2931113A patent/CA2931113C/en active Active
- 2014-12-18 JP JP2016541346A patent/JP7325166B2/ja active Active
- 2014-12-18 KR KR1020167014866A patent/KR102597804B1/ko active Active
- 2014-12-18 CA CA3204788A patent/CA3204788C/en active Active
- 2014-12-18 KR KR1020257033750A patent/KR20250154523A/ko active Pending
- 2014-12-18 EP EP14824722.4A patent/EP3083682B1/en active Active
- 2014-12-18 KR KR1020237037490A patent/KR20230155605A/ko not_active Ceased
- 2014-12-18 CN CN201480067934.5A patent/CN105849124B/zh active Active
-
2016
- 2016-05-19 MX MX2021003549A patent/MX2021003549A/es unknown
- 2016-05-27 US US15/167,030 patent/US10683348B2/en active Active
-
2020
- 2020-04-28 US US16/860,891 patent/US12006360B2/en active Active
- 2020-05-27 JP JP2020092097A patent/JP7504664B2/ja active Active
-
2023
- 2023-08-21 JP JP2023134016A patent/JP2023179409A/ja not_active Withdrawn
-
2024
- 2024-04-29 US US18/648,653 patent/US20240279327A1/en not_active Abandoned
- 2024-12-13 US US18/980,433 patent/US20250109195A1/en not_active Abandoned
-
2025
- 2025-07-25 US US19/280,650 patent/US20250346661A1/en active Pending
- 2025-08-08 JP JP2025133768A patent/JP2025179073A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501711A5 (index.php) | ||
| RU2016129247A (ru) | Антитела с двойной специфичностью | |
| CN104774266B (zh) | 白介素-13结合蛋白 | |
| JPWO2015095539A5 (index.php) | ||
| CA2896548A1 (en) | Multivalent binding protein compositions | |
| US20150344566A1 (en) | Dual specific binding proteins directed against il-13 and/or il-17 | |
| US20130171059A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| JP2019536806A5 (index.php) | ||
| JP2017535257A5 (index.php) | ||
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2013507929A (ja) | Ｉｌ−１結合蛋白質 | |
| JP2018521638A5 (index.php) | ||
| TW201446800A (zh) | 針對ＴＮＦα之雙特異性結合蛋白 | |
| JP2017529838A5 (index.php) | ||
| TW201031421A (en) | IL-1 binding proteins | |
| JP2014503202A (ja) | ＴＮＦ−α結合性タンパク質 | |
| EP2928919A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins | |
| JP2017533694A5 (index.php) | ||
| JP2010526028A5 (index.php) | ||
| TW201527322A (zh) | 骨關節炎及疼痛之治療 | |
| JP2020514277A5 (index.php) | ||
| JP2015503909A5 (index.php) | ||
| JP2017507131A5 (index.php) | ||
| JP2010520290A5 (index.php) | ||
| TW201402608A (zh) | Ｉｌ－１結合蛋白質 |